Aristotle Atlantic Partners’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$34.9M Sell
71,042
-2,566
-3% -$1.39M 1.63% 16
2025
Q4
$42.7M Sell
73,608
-1,040
-1% -$588K 1.95% 13
2025
Q3
$36.2M Sell
74,648
-1,727
-2% -$804K 1.05% 24
2025
Q2
$31M Buy
76,375
+10,222
+15% +$4.27M 0.94% 30
2025
Q1
$32.9M Buy
66,153
+2,298
+4% +$1.24M 1.11% 29
2024
Q4
$33.2M Sell
63,855
-1,068
-2% -$587K 1.04% 23
2024
Q3
$40.2M Sell
64,923
-23,021
-26% -$13.6M 1.25% 23
2024
Q2
$48.6M Sell
87,944
-20,799
-19% -$11.9M 1.58% 18
2024
Q1
$63.2M Sell
108,743
-21,933
-17% -$12.3M 2.06% 14
2023
Q4
$69.4M Buy
130,676
+8,947
+7% +$4.33M 2.44% 8
2023
Q3
$61.6M Buy
121,729
+7,990
+7% +$4.26M 2.47% 7
2023
Q2
$59.3M Buy
113,739
+10,804
+10% +$5.83M 2.23% 8
2023
Q1
$59.3M Buy
102,935
+5,515
+6% +$3.11M 3.05% 6
2022
Q4
$53.6M Buy
97,420
+1,225
+1% +$649K 3% 7
2022
Q3
$48.8M Buy
96,195
+36,389
+61% +$20.4M 2.97% 6
2022
Q2
$32.5M Buy
59,806
+1,505
+3% +$828K 2.5% 8
2022
Q1
$34.4M Buy
58,301
+863
+2% +$496K 2.13% 14
2021
Q4
$38.3M Buy
57,438
+2,638
+5% +$1.65M 2.22% 13
2021
Q3
$31.3M Sell
54,800
-4,520
-8% -$2.48M 2.07% 12
2021
Q2
$29.9M Buy
59,320
+675
+1% +$318K 1.97% 15
2021
Q1
$26.8M Sell
58,645
-1,695
-3% -$809K 1.96% 16
2020
Q4
$28.1M Sell
60,340
-137
-0.2% -$64.2K 2.17% 15
2020
Q3
$26.7M Buy
60,477
+827
+1% +$342K 2.35% 12
2020
Q2
$21.6M Buy
59,650
+2,706
+5% +$907K 2.08% 19
2020
Q1
$16.1M Sell
56,944
-1,598
-3% -$504K 2.47% 13
2019
Q4
$19M Buy
58,542
+1,047
+2% +$317K 2.43% 14
2019
Q3
$16.7M Buy
57,495
+876
+2% +$251K 4.82% 4
2019
Q2
$16.6M Buy
56,619
+861
+2% +$237K 4.83% 5
2019
Q1
$15.3M Sell
55,758
-136
-0.2% -$33.8K 4.64% 5
2018
Q4
$12.5M Buy
55,894
+7,494
+15% +$1.76M 4.41% 4
2018
Q3
$9.76M Sell
48,400
-4,860
-9% -$1.12M 5.97% 7
2018
Q2
$11M Buy
53,260
+736
+1% +$156K 3.83% 8
2018
Q1
$10.8M Buy
52,524
+518
+1% +$109K 3.91% 9
2017
Q4
$9.88M Buy
+52,006
New +$9.96M 3.54% 9

Other funds holding TMO

Aristotle Atlantic Partners's TMO Position: Q1 2026 in Review

Aristotle Atlantic Partners reduced its Thermo Fisher Scientific (TMO) stake by 3.5% in Q1 2026, selling an estimated $1.39M and leaving 71,042 shares worth $34.9M. The position accounts for 1.63% of the portfolio, ranked #16.

Aristotle Atlantic Partners first reported a position in TMO in Q4 2017 and has held it in 34 quarters since. The position peaked at $69.4M in Q4 2023. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Aristotle Atlantic Partners held 71,042 shares of Thermo Fisher Scientific worth $34.9M as of Q1 2026.
  • Aristotle Atlantic Partners sold 2,566 Thermo Fisher Scientific shares in Q1 2026, an estimated $1.39M.
  • Thermo Fisher Scientific made up 1.63% of Aristotle Atlantic Partners's portfolio in Q1 2026, its #16 holding.
  • Aristotle Atlantic Partners first reported a position in Thermo Fisher Scientific in Q4 2017 and has held it in 34 quarters since.
  • Aristotle Atlantic Partners's Thermo Fisher Scientific position peaked at $69.4M in Q4 2023.
  • 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Aristotle Atlantic Partners's 13F filing for Q1 2026, filed 15 May 2026.